Ann Pediatr Endocrinol Metab.  2021 Dec;26(4):266-271. 10.6065/apem.2040286.143.

Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs

• Rho JG
• Kum CD
• Seo YJ
• Shim YS
• Lee HS
• Hwang JS

• KMID: 2523833
• DOI: http://doi.org/10.6065/apem.2040286.143

Abstract

Purpose
Antithyroid drugs (ATDs) are primarily used as an initial treatment in pediatric patients with Graves’ disease (GD). We aimed to investigate the long-term outcomes in pediatric GD patients receiving ATDs.
Methods
Retrospective data from a single center were collected from April 2003 to July 2020. A total of 98 children and adolescents aged 2–16 years diagnosed with GD and receiving ATDs was enrolled. We investigated the factors correlated with remission by comparing children who achieved remission after 5 years and those with persistent disease.
Results
The study included 76 girls (77.6%) and 22 boys (22.4%). During the 5-year follow-up period, 18 children (18.3%) maintained remission, ATDs could not be discontinued in 74 patients (75.5%), and relapse occurred in 6 patients (6.2%). The remission group had significantly lower thyroid-stimulating hormone-binding inhibitory immunoglobulin (TBII) level at diagnosis (P=0.002) and 3 months (P=0.002), 1 year (P=0.002), 2 years (P≤0.001), 3 years (P≤0.001), 4 years (P≤0.001), and 5 years (P≤0.001) after ATD treatment than did the nonremission group. The remission group also had a shorter time for TBII normalization after ATD treatment (P≤0.001). Multiple logistic regression analysis showed that the time to TBII normalization (cutoff time=2.35 years) was related to GD remission (odds ratio, 0.596; 95% confidence interval, 0.374–0.951).
Conclusion
TBII level and time to TBII normalization after ATD treatment can be used to predict remission in pediatric GD patients.

Keyword

Graves' disease; Thyroid-stimulating hormone-binding inhibitory immunoglobulin; Antithyroid drugs; Remission

Reference

References

1. Song SM, Youn JS, Ko JM, Cheon CK, Choi JH, Yoo HW. The natural history and prognostic factors of Graves' disease in Korean children and adolescents. Korean J Pediatr. 2010; 53:585–91.

2. Weetman AP. Graves' disease. N Engl J Med. 2000; 343:1236–48.

3. Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol. 2014; 9:147–56.

4. Zimmerman D, Gan-Gaisano M. Hyperthyroidism in children and adolescents. Pediatr Clin North Am. 1990; 37:1273–95.

5. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr. 2008; 51:1–25.

6. World Health Organization. Indicators for assessing iodine deficiency disorders and their control through salt iodization. Geneva (Switzerland): World Health Organization;1994.

7. Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, Salerno M, et al. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr. 2014; 164:1189–94.e1.

8. Smith TJ, Hegedüs L. Graves' Disease. N Engl J Med. 2016; 375:1552–65.

9. Magri F, Zerbini F, Gaiti M, Capelli V, Ragni A, Rotondi M, et al. Gender influences the clinical presentation and long-term outcome of Graves disease. Endocr Pract. 2016; 22:1336–42.

10. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twentyfive percent remission every two years. J Clin Endocrinol Metab. 1987; 64:1241–5.

11. Gruñeiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves' disease: outcome and treatment. J Pediatr Endocrinol Metab. 2003; 16:1249–55.

12. Kaguelidou F, Carel JC, Léger J. Graves' disease in childhood: advances in management with antithyroid drug therapy. Horm Res. 2009; 71:310–7.

13. Lee SH, Lee SY, Chung HR, Kim JH, Kim JH, Lee YA, et al. Remission rate and remission predictors of Graves disease in children and adolescents. Korean J Pediatr. 2009; 52:1021–8.

14. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997; 82:1719–26.

15. Glaser NS, Styne DM; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group. Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics. 2008; 121:e481–8.

16. Hwang SM, Kim MS, Lee DY. Predictive factors for early response to methimazole in children and adolescents with Graves disease: a single-institute study between 1993 and 2013. Ann Pediatr Endocrinol Metab. 2016; 21:70–4.

17. Kim SM, Hwang JS. Remission predictors of Graves' disease in children. J Korean Soc Pediatr Endocrinol. 2010; 15:100–5.

18. Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res. 2004; 36:92–6.

19. Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, et al. Sensitive thyrotropin and thyrotropinreceptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid. 2005; 15:1047–54.

20. Maugendre D, Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf). 2001; 54:89–96.

21. Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. Eur J Endocrinol. 2002; 146:173–7.